SPRYCEL (™) (dasatinib)

SPRYCEL (dasatinib) has been issued marketing authorization with conditions for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

SPRYCEL(TM) (dasatinib) has been issued marketing authorization without conditions for the treatment of adults with:  Ph+ chronic, accelerated, or blast phase CML with resistance or intolerance to prior therapy including imatinib mesylate;  Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.